PLOSBRIO DIN 02564076
Health Canada record
| Active ingredient(s) | SEMAGLUTIDE 1.34 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | A10BJ06 SEMAGLUTIDE |
| Original market date | |
| Current status date | 22-Dec-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novo Nordisk Canada Inc — licence 100175, currently licensed, last inspection rating C (2023-02-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SEMAGLUTIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02568020 | APO-SEMAGLUTIDE INJECTION | APOTEX INC | Solution | SEMAGLUTIDE 0.68 MG | Marketed |
| 02568012 | APO-SEMAGLUTIDE INJECTION | APOTEX INC | Solution | SEMAGLUTIDE 1.34 MG | Marketed |
| 02569949 | ASPEN-SEMAGLUTIDE | ASPEN PHARMACARE CANADA INC. | Solution | SEMAGLUTIDE 1.34 MG | Approved |
| 02569930 | ASPEN-SEMAGLUTIDE | ASPEN PHARMACARE CANADA INC. | Solution | SEMAGLUTIDE 1.34 MG | Approved |
| 02562618 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1.34 MG | Approved |
| 02471469 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1.34 MG | Marketed |
| 02523930 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2.68 MG | Approved |
| 02562626 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2.68 MG | Approved |
| 02540258 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 0.68 MG | Marketed |
| 02564068 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1.34 MG | Approved |
| 02568233 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1.34 MG | Approved |
| 02568241 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2.68 MG | Approved |
| 02564041 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 0.68 MG | Approved |
| 02564084 | PLOSBRIO | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2.68 MG | Approved |
| 02564211 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 9.6 MG | Approved |
| 02564106 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 0.25 MG | Approved |
| 02564114 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 0.5 MG | Approved |
| 02564122 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1 MG | Approved |
| 02564130 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1.7 MG | Approved |
| 02564149 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2.4 MG | Approved |
| 02564157 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1 MG | Approved |
| 02564165 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2 MG | Approved |
| 02564173 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2 MG | Approved |
| 02564181 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 4 MG | Approved |
| 02564203 | POVIZTRA | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 6.8 MG | Approved |
| 02497603 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | SEMAGLUTIDE 7 MG | Marketed |
| 02551012 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | SEMAGLUTIDE 1.5 MG | Marketed |
| 02551020 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | SEMAGLUTIDE 4 MG | Marketed |
| 02497581 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | SEMAGLUTIDE 3 MG | Marketed |
| 02551039 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | SEMAGLUTIDE 9 MG | Marketed |
| 02497611 | RYBELSUS | NOVO NORDISK CANADA INC | Tablet | SEMAGLUTIDE 14 MG | Marketed |
| 02567814 | SEMAGLUTIDE INJECTION | DR REDDY'S LABORATORIES LTD | Solution | SEMAGLUTIDE 1.34 MG | Marketed |
| 02567806 | SEMAGLUTIDE INJECTION | DR REDDY'S LABORATORIES LTD | Solution | SEMAGLUTIDE 1.34 MG | Marketed |
| 02570912 | SEMAGLUTIDE INJECTION | ASPEN PHARMACARE CANADA INC. | Solution | SEMAGLUTIDE 1.34 MG | Approved |
| 02570920 | SEMAGLUTIDE INJECTION | ASPEN PHARMACARE CANADA INC. | Solution | SEMAGLUTIDE 1.34 MG | Approved |
| 02569582 | SEVMIA | APOTEX INC | Solution | SEMAGLUTIDE 4 MG | Approved |
| 02522594 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1.7 MG | Approved |
| 02522551 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 0.25 MG | Approved |
| 02528525 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 4 MG | Marketed |
| 02522586 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1 MG | Approved |
| 02528541 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 9.6 MG | Marketed |
| 02522578 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 0.5 MG | Approved |
| 02552698 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2 MG | Approved |
| 02528533 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 6.8 MG | Marketed |
| 02528517 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2 MG | Marketed |
| 02528509 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1 MG | Marketed |
| 02522608 | WEGOVY | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 2.4 MG | Approved |
| 02471477 | OZEMPIC | NOVO NORDISK CANADA INC | Solution | SEMAGLUTIDE 1.34 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36610 | 2025-12-22 | New Drug Submission (NDS) | Administrative – Additional product name |
International API supply for SEMAGLUTIDE
95 active FDA Drug Master Files.
Request a quote for PLOSBRIO